A quick sniff of a nasal spray sends microscopic metal particles into the brain, where they target and destroy the damaging proteins of Alzheimer’s disease.
No Alzheimer’s? No problem—the metal particles pass out of the body safely. Such is the promise of technology being developed by neuroscientist William Klein and nanotechnologist Vinayak Dravid of Northwestern University. The pair has invented a nanotech-based early-detection system that might one day deliver targeted treatments.
Klein and Dravid created an antibody—an immune molecule that detects specific chemical structures—that binds to a particle implicated in Alzheimer’s. They linked the antibody to a nanoscale arrangement of iron oxide compounds, similar to rust, which can be seen with magnetic resonance imaging. The brain scan could detect the disease early on, so patients can start treatment sooner than they can today. “Once the chain reaction of negative events starts, it’s like a lit fuse. You want to intervene as soon as possible,” Klein says.
Globs of beta-amyloid protein called plaques are a hallmark of Alzheimer’s. But these days most neuroscientists agree that a tiny particle form of the same protein, called an oligomer, is the primary toxin in the illness. Eventually these smaller structures glom together to form plaques, but by then they have already damaged brain cells. The antibody created at Northwestern binds to the toxic oligomers and could one day deliver therapies to the brain or help clinicians evaluate how a patient is responding to a new medication.
The Latest Bing News on:
- Precision medicine helps identify 'at-risk rapid decliners' in early-stage kidney diseaseon July 8, 2021 at 10:48 am
Diabetes is the leading cause of kidney failure in the United States, but identifying type 1 or type 2 diabetes patients at high risk for progressive kidney disease has never had a sure science behind ...
- FDA, facing intense criticism, narrows use of controversial Alzheimer’s drug to patients with early-stage diseaseon July 8, 2021 at 9:40 am
The revised label clarifies that the drug, called Aduhelm, is intended for patients with early-stage disease — the population that participated in clinical trials of the drug.
- U.S. FDA updates label for Biogen's Alzheimer's drug to specify disease stageon July 8, 2021 at 8:44 am
Biogen Inc (BIIB.O) said on Thursday the U.S. Food and Drug Administration has approved changes to the product information for its Alzheimer's disease drug to specify that it has not been studied in ...
- Adults With Obesity See Increased Risk for Crohn's Diseaseon July 8, 2021 at 8:30 am
Obesity in adulthood was associated with a 34% increased risk for developing Crohn's disease, while no such link was seen with ulcerative colitis, a pooled analysis of large prospective studies found.
- Brain research uncovers 'perfect storm' linked to neurodegenerative diseaseon July 8, 2021 at 6:47 am
A "perfect storm" of genetic mutations, toxic proteins and a defect in natural cell recycling has been uncovered in University of Queensland research that could lead to treatments for ...
- Alzheimer’s Disease and Brain Injury Disrupt Microtubular Meshes to Trigger Nerve Cell Deathon July 8, 2021 at 5:00 am
New research from scientists at the University of Plymouth shows disruption of the microtubular cytoskeleton triggers cells in the midline in fruit fly embryos to divide. The scientists report ...
- Cancer death rates have dropped. But experts warn obesity may soon drive the disease.on July 8, 2021 at 3:54 am
The annual report of cancer deaths paints a mixed picture of the nation's effort to combat the second leading cause of death, experts say.
- Tay-Sachs Disease Drugs Market Size, Share, Growth and Report, 2030on July 7, 2021 at 11:34 pm
Research Nester released a report titled "Tay- Sachs Disease Drug Market: Global Demand Analysis & Opportunity ...
- In search of how memory fails, Alzheimer's disease study provides rare insight, thanks to ratson July 7, 2021 at 10:57 am
A University of Texas study published last month revealed for the first time what happens when the brain makes a memory mistake.
- A leading US disease expert says there's 'no doubt in my mind' that vaccinated people are helping spread Deltaon July 7, 2021 at 9:22 am
Christopher Murray, director of the IHME, which the White House leans on for COVID-19 data, says we shouldn't drop our masks yet, especially indoors.
The Latest Google Headlines on:
The Latest Bing News on:
Nanotech-based early-detection system
- Feed has no items.